Corcept Therapeutics | CORT - Selling And Administration Expenses


Corcept Therapeutics reported $156.9M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Alaunos Therapeutics USD 447K 138K Mar/2026
ANI Pharmaceuticals USD 73.66M 9.14M Mar/2026
Ardelyx USD 102.27M 26.35M Mar/2026
Aurora Cannabis CAD 41.4M 781K Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Canopy Growth CAD 31.17M 2.27M Mar/2026
Corcept Therapeutics USD 156.9M 28.85M Jun/2026
Eli Lilly USD 2.93B 198M Mar/2026
J&J USD 6.42B 381M Jun/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Lexicon Pharmaceuticals USD 3.98M 195K Dec/2025
Merck USD 2.89B 219M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Novartis USD 3.24B 101M Jun/2026
Novartis USD 3.14B 296M Mar/2026
Omeros USD 11.32M 2.48M Sep/2024
Pacira USD 91.81M 7.93M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Supernus Pharmaceuticals USD 133.64M 15.41M Jun/2026
TG Therapeutics USD 62.32M 10.82M Jun/2026